Imperial College London

ProfessorGavinScreaton

Faculty of MedicineDepartment of Immunology and Inflammation

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 7594 1190g.screaton Website

 
 
//

Assistant

 

Ms Claire Puddephatt +44 (0)20 7594 1190

 
//

Location

 

2.15Faculty BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Screaton:2018:10.1101/cshperspect.a029520,
author = {Screaton, G and Mongkolsapaya, J},
doi = {10.1101/cshperspect.a029520},
journal = {Cold Spring Harbor perspectives in biology},
title = {Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine},
url = {http://dx.doi.org/10.1101/cshperspect.a029520},
volume = {10},
year = {2018}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - A dengue vaccine has been pursued for more than 50 years and, unlike other flaviviral vaccines such as that against yellow fever, progress has been slow. In this review, we describe progress toward the first licensed dengue vaccine Dengvaxia, which does not give complete protection against disease. The antibody response to the dengue virion is reviewed, highlighting immunodominant yet poorly neutralizing responses in the context of a highly dynamic structurally flexible dengue virus particle. Finally, we review recent evidence for cross-reactivity between antibody responses to Zika and dengue viruses, which may further complicate the development of broadly protective dengue virus vaccines.
AU - Screaton,G
AU - Mongkolsapaya,J
DO - 10.1101/cshperspect.a029520
PY - 2018///
SN - 1943-0264
TI - Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine
T2 - Cold Spring Harbor perspectives in biology
UR - http://dx.doi.org/10.1101/cshperspect.a029520
UR - http://hdl.handle.net/10044/1/54013
VL - 10
ER -